Sanofi to Cut US Price of Its Most-Prescribed Insulin by 78%
Sanofi said on Thursday it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly.
Stay updated with breaking news from Patrick Wingrove. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sanofi said on Thursday it will cut US list prices for its most-prescribed insulin product, Lantus, by 78% starting next year after similar moves by rivals Novo Nordisk and Eli Lilly.
The collapse of Silicon Valley Bank will leave early-stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly-traded drug companies should... | March 13, 2023
The collapse of Silicon Valley Bank will leave early stage biotechnology companies with a funding void, investors and analysts said on Monday, but larger, publicly traded drug companies should escape unscathed.
The White House budget request includes plans to strengthen the FDA’s regulatory authority.
The blood thinner Eliquis from Bristol Myers Squibb, Pfizer's breast cancer drug Ibrance and AbbVie's leukemia treatment Imbruvica are likely to be among 10 big-selling medicines subject to U.S.... | March 13, 2023